Hansa Biopharma announced the closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA Hansa Biopharma AB and SERB S.A. announced that the required regulatory approvals have been obtained and that the previously announced €115 million exclusive licensing transaction with SERB has closed. The company also announced that Maria Törnsén, […]
– New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – Deal worth up to $415m including upfront and downstream, plus royalties on top – ATLX-1282 is the first programme out of Alchemab’s entirely novel platform which generates and analyses millions of antibody sequences […]
Optimum is a proud sponsor of ON Helix. This one-day conference will address key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools or treatments. Delegates and Supporters will connect with the One Nucleus network to explore New Horizons for Bio Innovation. ON Helix Key […]
STC-15 is the first METTL3 inhibitor to enter clinical development Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients 9 October 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]
One Nucleus’ On Helix Conference 2023, provided insight into the current climate for Biotech companies, including the international outlook, and what to expect in the future. The past few years have been tough for the international Biotech market, with funding, Brexit, new regulations, trade agreements and supply chain issues. Additionally, valuations have fallen and consequently […]
